Welcome to the HBV Advocate’s AASLD Conference coverage.  In an effort to best serve our readership, we will post all the important and interesting abstracts about HBV from the conference.  While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted.  The other abstracts posted to the web site are HBV related abstracts posted to www.aasld.org that we have not been able to report on or update.  

 

To locate specific abstracts for each topic below, click on the links.

 

Please click here to view our fact sheet on reading and understanding an abstract.

 

Thank You,

Alan Franciscus

Editor-in-Chief

 

 

 

Hepatitis B

 

 

Antivirals

 

·        Adefovir

o       946.Characterization of Hepatitis B Virus Polymerase Mutations Detected During Antiviral Treatment with Adefovir Dipivoxil (ADV)

o       955. Drug Susceptibility Testing of a Novel Mutation Pattern (A181S+M204I) Conferring Resistance to Lamivudine and Adefovir Dipivoxil

o       956.Adefovir Dipivoxil Plus Lamivudine Combination Treatment Is Superior to Adefovir Dipivoxil Monotherapy in Lamivudine-resistant Hepatitis B e Antigen-negative Chronic Hepatitis B Patients

o       961. The Effect of Lamivudine and Adefovir Dipivoxil on Preventing Hepatocellular Carcinoma in Hepatitis B Virus-related Liver Cirrhosis

o       964. Mutations of the HBV-polymerase Gene Associated with Adefovir Drug Resistance in Patients Undergoing a First Adefovir Therapy

o       981. Clinical Covariates Associated with Virological Response and Adefovir Resistance in Chronic Hepatitis B (HbeAg)- negative Lamivudine-resistant Patients Treated with Adefovir Alone or in Combination with Lamivudine for 28 months

o       982. Factors Affecting Response To Adefovir Treatment In Patients With Chronic Hepatitis B And Lamivudine Resistance

o       983. Predictors of Virologic Response and Resistance to Adefovir in Patients With Lamivudine-resistant Chronic Hepatitis B Virus Infection

o       996. Impact of Adefovir Dipivoxil on Liver Fibrosis and Activity Assessed with FibroTest-ActiTest in Patients Infected by Hepatitis B Virus

o       998. Factors Affecting Initial Virologic Response and Emergence of Resistant Mutants after Adefovir Treatment in Lamivudine-resistant Chronic Hepatitis B Patients

o       1000. Adefovir Depivoxil for Decompensated Liver Cirrhosis Patients with Lamivudine-resistant Hepatitis B: Multi-center Long-term Results

 

·        Entecavir

o       938. Four-Year Entecavir Treatment in Nucleoside-Naďve HBeAg(+) Patients: Results from Studies ETV-022 and -901

o       951. Entecavir: A Rescue Therapy for Chronic Hepatitis B Patients with a Limited Virological Response to Adefovir?

o       963. Emergence of Hepatitis B Virus Gene Mutation Related to Entecavir-resistance in Chronic Hepatitis B Patients Participating in the Phase 2 Clinical Studies of Entecavir in Japan

o       997. Long-term Follow-up of Entecavir Treated Protocol-defined Nonresponders in Rollover Study ETV-901

o       1003. Three-year Assessment of Entecavir Resistance in Genotype C Chronic Hepatitis B Patients in Japan Reveals Different Clinical Outcomes Regarding Breakthrough Hepatitis Predicted by the Resistance Substitutions Using Recently-developed INNO-LiPA HBV Assay

 

·        Lamivudine

o       957. Pretreatment Alanine Transaminase Level Might Not Be the Most Important Factor in Predicting HBeAg Loss in Older Patients with More Prolonged HBV Infection

o       947. Durability of Antiviral Response in Lamivuidne-Treated HBeAg Positive Chronic Hepatitis B Patients Who Did Not Relapse Within a Year of Post-Treatment

o       948. Analysis of Determinants for Sustained Virologic Response to Lamivudine Monotherapy in Patients with HBeAg Positive Chronic Hepatitis B: A Multi-center Trial

o       950. Variability of the HBV Pol Gene Reverse-Transcriptase Domain in Viral Isolates from Untreated and Lamivudine-resistant Chronic Hepatitis B Patients

o       956. Adefovir dipivoxil plus lamivudine combination treatment is superior to adefovir dipivoxil monotherapy in lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B patients

o       957. Pretreatment Alanine Transaminase Level Might Not Be the Most Important Factor in Predicting HBeAg Loss in Older Patients with More Prolonged HBV Infection

o       959. Does the Genotoxic Effect of Lamivudine Treatment in Chronic Hepatitis B to the Host DNA?

o       966. Prediction of Long-term Maintenance of Virologic Response During Lamivudine Treatment in HBeAg-Negative Chronic Hepatitis B

o       972. Long-term Follow-up of Chinese Patients with HBeAg-negative Chronic Hepatitis B Who Discontinued Treatment after Twp Years of Lamivudine Monotherapy

o       977. Restoration of HBV-Specific T Cell Responses in Lamivudine Long-term Responder

o       989. Profiles of HBV DNA, ALT and HBeAg Status After Stopping Lamivudine in Patients with HBeAg Seroconversion

o       999. Prognostic Factors that Associated with Hepatitis B Virus DNA Breakthrough in Chronic Hepatitis B Patients with Lamivudine Treatment

 

·        Telbivudine

o       940. Creatine Kinase (CK) Elevations and Muscle Toxicities Associated with Chronic Telbivudine (LdT) Use in Prospective Clinical Trials

o       994. Baseline Parameters Predict Both Early Virologic Response and Longer Term Outcomes for Telbivudine-Treated Patients With Chronic Hepatitis B (The Globe Study)

o       995. On-Treatment Virologic Suppression at Week 24 Decreases the Risk of Histologic Progression at One Year; Data from the GLOBE Trial

 

·        Tenofovir

o       LB6. A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg Positive Chronic Hepatitis B (CHB): Study GS-US-174-0103

o       83. First Multicenter Evaluation of the Efficacy of Tenofovir in Nucleos(t)ide Analog Experienced Patients with HBV Monoinfection

o       LB2. A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg-Negative Chronic Hepatitis B (CHB): Study GS-US-174-0102

o       960. Tenofovir Shows Limited Efficacy in Treatment of HBV Infections Resistant Against Adefovir

 

Antiviral Resistance/Mutations

·        949. Multidrug Resistance and Cross-Resistance Pathways in HBV as a Consequence of Treatment Failure

·        976. Drug Resistance Mutation Analysis by Different Methods in a Highly Treatment-experienced Chronic Hepatitis B Patient Population

·        980. Very High Prevalence of Precore (preC) and/or Basal Core Promoter (BCP) Mutations (Mut) in HBeAg-positive (eAg+) and -negative (eAg-) Chronic Hepatitis B (CHB) Especially Among Older Patients

·        986. A Hepatitis B Virus Mutant Implicated In Non-Response To Sequential Treatment With Adefovir, Lamivudine And Entecavir Shows Cross-Resistance To Multiple Antiviral Agents

·        987. Cost-effectiveness of New Treatment Paradigms for HBeAg-negative Chronic Hepatitis B

·        1005. Cross-resistance Characterization of the Main HBV Drug-resistant Mutants

·        1006. Detection of Hepatitis B Virus YMDD Mutants by Mltiplex-PCR Using Dual Priming Oligonucleotide (DPO)

·        1007. Five-year Retrospective Survey of HBV Genotypic Drug Resistance Patterns in a Database of 381 HBV Reverse Transcriptase Sequences in Southern France.

 

Children and HBV

·        1090. Unique Full Length Hepatitis B Virus Genomes Isolated from Children With Hepatocellular Carcinoma

·        1093.Treatment of Hepatitis B Using Intron A vs. Peginterferon in Combination with Lamivudine in Children

·        1094. HBeAg Seroconversion Correlates with a High Number of Core Gene Mutations and with Genotypes B and D in Pediatric Patients

·        1095. Graft Histology Up to 10 Years after Pediatric Liver Transplantation: High Incidence of Severe Fibrosis, Correlated with Transplant-related Factors

·        1095. Graft Histology Up to 10 Years after Pediatric Liver Transplantation: High Incidence of Severe Fibrosis, Correlated with Transplant-related Factors 

 

Disease Progression

·        897. In Vitro Infection of Immortalized Human Hepatocytes by Hepatitis B Virus and Its Application to Anti-viral Treatment

·        898. The Role of Serial Measurement of Serum HBV-DNA Levels in Patients with Chronic HBeAg(-) Hepatitis B Infection; Association with Liver Disease Progression: A Prospective Cohort Study

·        900. Large Scale Longitudinal Study of Chronic Hepatitis B Patients with Hepatitis B Surface Antigen Seroclearance

·        902. Reduced HBV Rreplication in HBeAg-negative Patients Is Due to Lower Covalently Closed Circular DNA Content and Impaired Virion Productivity

·        903. High Viral Load and Hepatitis B Virus (HBV) Subgenotype Ce Have Increased Risk of Hepatocellular Carcinoma (HCC) – A 7-year Prospective Follow-up Study

 

HIV/HBV Coinfection

·        1480. Liver Disease Progression Among HIV-infected Patients with Viral Hepatitis

 

Interferon

·        941. Mutations in Immunodominant Epitopes of Hepatitis B Virus (HBV) Core Region: Enhancement of Viral Evolution by the Effect of Interferon Therapy

·        953. Demonstration of an Association Between Detection of IgG Antibody Reactivity Towards the C-terminal Region of the preS1 Protein of Hepatitis B Virus and the Capacity to Respond to Interferon Therapy in Chronic Hepatitis B

·        109. In vitro and in vivo Inhibition of HBV Replication by Peptide Aptamers via Disruption of the HBX-Proteasome Interaction

·        962. The Indication and Limitation of Interferon Therapy as the First Line Therapy of Chronic Hepatitis B from the Histological Analysis of 800 Chronic Hepatitis B Patients

·        1002. Predicting Sustained HBeAg Loss after Treatment with Peginterferon alpha-2b: Development and Validation of a Practical Model

·        965. Sustained HBeAg and HBsAg Loss after Long-term Follow-up of HBeAg-Positive Patients Treated with Peginterferon alpha-2b

·        974. Not HBeAg-status But HBV Genotype Predicts Response to Interferon in Chronic hepatitis B

·        978. Twenty-four Weeks of Therapy with Peginterferon alfa-2a Is Similar to 48 weeks of Therapy in Patients with HBeAg-positive Chronic Hepatitis B and Good Predictors of Response

·        979. Long-term Follow-up of HBsAg Clearance in Patients with HBeAg-negative CHB Treated with Peginterferon alfa-2a: Increase in HBsAg Clearance Rate from 3% Six Months Post-treatment to 8% after Three Years

·        990. Reduction in Serum HBsAg Level in Patients with Chronic Hepatitis B Infected with Genotype D Induced by (pegylated) Interferon alfa-2a Alone or in Combination with Nucleos(t)ide Analogs: A Long-term Single Center Cohort Study

·        991. High Rates of HBsAg Seroconversion in Chronic Hepatitis B Patients Responding to Interferon Therapy: a Long-term Follow-up Study

·        992. HBsAg Seroconversion: Different Kinetics of Serum HBsAg Level Decrease in Inactive Carriers and Chronic Hepatitis B Patients Treated with Interferon

 

Liver Cancer

·        374. The Effect of Sustained HBV Viremia on the Recurrence of Hepatocellular Carcinoma After Curative Resection

·        376. Early Diagnosis Panel of Serum Biomarkers of HBV-Induced Hepatocellular Carcinoma During 3 Years Follow-up

·        389. MicroRNA Expression Profiling Combined with Analysis of Target Gene Expression in Chronic Viral Hepatitis and Hepatocellular Carcinoma

·        397. Polymorphisms of DNA Repair Genes XRCC3, ERCC5/XPG and Risk of Hepatocellular Carcinoma in Korean with Chronic Hepatitis B Infection

·        400. Hepatitis B Virus X Gene Mutations Are Common in Patients Both With or Without Hepatocellular Carcinoma and Further Mutations Occur When Hepatocellular Carcinoma Develops

·        401. Trends in the Incidence of Hepatocellular Carcinoma in Singapore 1968-2002

·        402. The Changing Epidemiology and Etiology of Hepatocellular Carcinoma from 1969 Through 2006 in Alaska Native People

·        403. Prognostic Factors Affecting 3 Years Survival in Patients with Hepatocellular Carcinoma (HCC

·        411. Polymorphism of Interleukin-18 Is a Risk Factor for the Clearance of Hepatitis B Virus Infection and Hepatocellular Carcinoma Development

·        415. Genetic Polymorphisms Associated with Clearance of Hepatitis B Virus Infection and Hepatocellular Carcinoma Occurrence Detected by SNP Chips

·        420. Serum Antibody to Hepatitis B Core Antigen Is Not Associated with Increased Risk of Hepatocellular Carcinoma (HCC) in Patients with HCV-related Cirrhosis

 

Liver Transplantation

·        11. A Randomized Study to Assess the Safety and Efficacy of Adefovir Dipivoxil Substitution for Hepatitis B Immune Globulin in Liver Transplantation Patients Receiving Long-term Low-dose IM HBIg and Lamivudine Prophylaxis

·        12. Decline in the Need for Liver Transplantation for End Stage Liver Disease secondary to Hepatitis B in the United States

·        28. Survival and Risk of Hepatitis B Virus (HBV) Recurrence in HIV-HBV Coinfected Liver Transplant Recipients: Preliminary Findings from the HIV-TR Study

 

New Antivirals

·        952. Combination Antiviral Effects of 2’, 3’-dideoxy-3’fluoroguanosine with Nucleos(t)ide Analogs Against Hepatitis B Virus In-vitro

·        110.  Induction of Antigen-specific Humoral and Cellular Immune Responses by Antigen-pulsed Human Blood Dendritic Cells in Hepatitis B Vaccine Nonresponders and Patients with Chronic Hepatitis B

·        111. Powerful inhibition of hepatitis B virus replication by CpG-induced cytokines in combination with lamivudine in vitro

·        1121. Long-Term Inhibition of Hepatitis B Virus Replication Using the Non-viral Episomal Vector pEPI-1

·        113. Adeno-associated Virus Rep78 Protein Inhibits Human Hepatitis B Virus Replication in Human Cells by Binding to X Promoter and C Promoter of HBV

·        114. Construction of the shRNA Plasmid of Human fgl2 Prothrombinase Gene and Its Effect on hfgl2 Expression In-vitro

·        985. Hepatitis B Surface Antigen Titer Was Decreased During Clevudine Therapy

·        1004. The Effects of α-galactosylceramide on Chronic Hepatitis B Infection in a Randomized Placebo-Controlled Phase I/II Trial

 

Prevention and Screening

·        1457. Screening for Hepatitis B Virus (HBV) Infection by Primary Care Physicians in New York City: Are Screening Recommendations for Persons Born in Endemic Countries Being Followed?

·        1473. Clinical and Laboratory Characteristics of Pregnant Women Chronically Infected with Hepatitis B Virus (HBV)

·        147. A Novel Therapeutic HBV Vaccine Induces Potent Surface- and Core-specific Immunogenicity in Mice, Rhesus Macaques and HBV Transgenic Mice

·        967. Amino Acid Variability within Hepatitis B Surface Antigen and the Overlapping Reverse Transcriptase Region in HBsAg-Negative/HbcAb-Positive Patients Presenting HBV Reactivation While Undergoing Chemotherapy and/or Stem Cell Transplantation for Cancer

·        970. Liver Biopsy: Still Essential in the Management of Chronic Hepatitis B

·        975. Intrahepatic and Serum Markers of HBV Replication and Their Relationship to Serum HBeAg Titers: Implications for the Use of Quantitative HBeAg Testing as a Predictive Tool for Treatment Outcome

·        984. Management of Chronic Hepatitis B Virus (HBV) Infection by Primary Care Physicians in Urban Hospitals and Clinics in New York City

·        988. Screening for Hepatitis B in Chemotherapy Patients: Survey of Current Oncology Practices

·        993. High Prevalence of Significant Histologic Disease in Patients with Chronic Hepatitis B and Normal ALT

·        1001. Clinical Features of Lymphoma Chemotherapy Associated Hepatitis Virus B Reactivation.

·        1008. Inflammation and Fibrosis in Patients with Chronic Hepatitis B Despite Low Viral Load at the Time of Liver Biopsy

·        901. FibroTest® (FT) and ActiTest® (AT) Accurately Predict Risk of Liver Decompensation and Death in Patients with Chronic Hepatitis B (CHB)

·        1457. Screening for Hepatitis B Virus (HBV) Infection by Primary Care Physicians in New York City: Are Screening Recommendations for Persons Born in Endemic Countries Being Followed?

·        1473. Clinical and Laboratory Characteristics of Pregnant Women Chronically Infected with Hepatitis B Virus (HBV)

·        1481. Diagnostic Accuracy of Blood Tests of Liver Fibrosis in Chronic Hepatitis B: Comparison with Hepatitis C

 

Treatment

 

Barriers

·        1474. Barriers to Viral Hepatitis Treatment for At-Risk Groups: Impacts of Policies and Processes

 

Guidelines

·        936. Predictors Of Significant Histological Findings In Chronic Hepatitis B Patients With Persistently Normal ALT Levels

·        937. Treatment-induced HBeAg Seroconversion Is a Poor Therapeutic Endpoint

·        942. A High Prevalence of Significant Liver Disease in Asymptomatic Hepatitis B Patients with High Viral Load; Candidates for Antiviral Therapy

·        944. Oncologists and Hepatitis B: Results of a Questionnaire Survey to Determine Their Current Level of Awareness and Clinical Practice of Antiviral Prophylaxis to Prevent Reactivation

·        945. Pre-emptive Lamivudine Reduces the Risk of Chemotherapy-Induced HBV-Related Morbidity and Mortality in HBsAg-Positive Cancer Patients: Meta-analysis

·        968.Estimating the Impact of Chronic Hepatitis B on Future Liver-related Morbility, Mortality and Cost in Spain

·        971. Predictors of Liver Decompensation in HBeAg–negative Patients with Chronic Hepatitis B

 

Virology

·        87. Dual Over-expression of Insulin Receptor Substrate-1 and Hepatitis Bx Gene Causes Pre-malignant Changes in Liver

·        111. Powerful Inhibition of Hepatitis B Virus Replication by CpG-induced Cytokines in Combination with Lamivudine In Vitro

·        109. In Vitro and In Vivo Inhibition of HBV Replication by Peptide Aptamers Via Disruption of the HBX-Proteasome Interaction

·        110. Induction of Antigen-Specific Humoral and Cellular Immune Responses by Antigen-Pulsed Human Blood Dendritic Cells in Hepatitis B Vaccine Nonresponders and Patients with Chronic Hepatitis B

·        112. Long Term Inhibition of Hepatitis B Virus Replication Using the Non Viral Episomal Vector pEPI-1

·        113. Adeno-associated Virus Rep78 Protein Inhibits Human Hepatitis B Virus Replication in Human Cells by Binding to X Promoter and C Promoter of HBV

·        114. Construction of the shRNA Plasmid of Human fgl2 Prothrombinase Gene and Its Effect on hfgl2 Expression In Vitro

·        146. Chronic HBV Evolution Is Associated with Numeric and Phenotypic Changes in Peripheral HBV-core Epitope-Specific CD4+ T-cells: A Study Using a Novel HBV-core-Specific HLA-DRB1*0101 Tetramer for the Analysis of Antiviral CD4+ T-cell Responses During Acute and Chronic Hepatitis B

·        146. Chronic HBV Evolution Is Associated with Numeric and Phenotypic Changes in Peripheral HBV-core Epitope-specific CD4+ T-cells: A Study Using a Novel HBV-core Specific HLA-DRB1*0101 Tetramer for the Analysis of Antiviral CD4+ T-cell Responses During Acute and Chronic Hepatitis B

·        1031. Higher Percentages of Intra-Hepatic Regulatory T Cells Are Present in Chronic Hepatitis B Patients with a High Viral Load

·        1032. Antigen-pulsed Dendritic Cells Are Capable of Inducing Both Innate ad Adaptive Immunity: A Lesson Learned from Cross-Talk Between Natural Killer Cells and Dendritic Cells and Their Application for Immune Therapy of Chronic Hepatitis B Virus Infection

·        1042. Expression of Notch Signaling and Antigen Processing Molecules in Progressive Pathogenenic Biopsies of Chronic Hepatitis B Infection

·        1043. Intrahepatic Status of Regulatory T cells in Autoimmune Hepatitis, Primary Biliary Cirrhosis, Chronic Hepatitis C, and Chronic Hepatitis B

·        1460. Differential Role of Liver-targeted Regulatory T Cell to Hepatitis B and C Virus in Chronically Infected Patients

·        1467. Quantitative Detection of Integrated HBV Surface Gene Sequences in the Liver by Real-Time PCR